Enzyme mechanism

Intuition [Beginner]

Enzymes are protein catalysts. They speed up reactions by factors of $10^6$ to $10^{17}$ without being consumed. The key idea: enzymes lower the activation energy — the energy hill that reactants must climb to reach the transition state — by providing an alternative reaction pathway through the enzyme's active site.

Three catalytic strategies account for most enzyme mechanisms. Acid-base catalysis: the enzyme donates or accepts a proton, helping bonds form or break. Covalent catalysis: the enzyme forms a temporary covalent bond with the substrate, creating a reactive intermediate that breaks down to product. Metal ion catalysis: a metal ion in the active site stabilises negative charges, polarises bonds, or generates a powerful nucleophile from water.

The active site is a small pocket or cleft on the enzyme surface where the substrate binds. Only a few of the enzyme's hundreds of amino acids participate directly in catalysis; the rest of the protein provides the three-dimensional scaffold that positions those key residues with sub-angstrom precision. The active site is complementary in shape and charge to the transition state of the reaction, not to the substrate — this is transition-state stabilisation, the central principle of enzyme catalysis.

The rate equation that describes the simplest enzyme behaviour is the Michaelis-Menten equation: $v=V_{max}[S]/(K_M+[S])$. Here $V_{max}$ is the maximum rate at saturating substrate, $K_M$ is the substrate concentration at half-maximal rate, and the ratio $k_{cat}/K_M$ (catalytic efficiency) measures how efficiently the enzyme converts substrate to product at low concentrations. When $k_{cat}/K_M$ approaches $10^8$ to $10^9$ ${\mathrm{M}}^{-1}{\mathrm{s}}^{-1}$, the enzyme is "catalytically perfect" — every collision with substrate produces product.

Visual [Beginner]

The active site is a pocket shaped to hold the substrate and the transition state. The substrate enters, the enzyme stabilises the transition state, and the product leaves.

The diagram shows how three amino acids, positioned by the protein scaffold, cooperate to hydrolyse a peptide bond. Ser provides the nucleophile, His shuttles protons, and Asp stabilises the charged form of His.

Worked example [Beginner]

Chymotrypsin hydrolyses a peptide bond through a catalytic triad and an acyl-enzyme intermediate.

Chymotrypsin digests proteins by cleaving peptide bonds on the C-terminal side of aromatic amino acids (Phe, Tyr, Trp). Its active site contains three amino acids — Ser195, His57, Asp102 — that work together as the catalytic triad.

Step 1: Substrate binding. The peptide enters the active site. The aromatic side chain of the target residue fits into a hydrophobic pocket, positioning the peptide carbonyl next to Ser195.

Step 2: Acyl-enzyme formation (acylation). His57 acts as a general base, abstracting the proton from Ser195's hydroxyl. The resulting alkoxide ($\mathrm{Ser}-{\mathrm{O}}^{-}$) attacks the peptide carbonyl carbon. A tetrahedral intermediate forms with a negatively charged oxyanion, which is stabilised by hydrogen bonds from backbone NH groups in the oxyanion hole. This intermediate collapses: the C-N bond breaks, the amine fragment leaves, and His57 donates its proton to the departing amine (now acting as a general acid). The enzyme is left with the acyl group covalently attached to Ser195.

Step 3: Deacylation. A water molecule enters the active site. His57 deprotonates water, generating $H{O}^{-}$, which attacks the acyl-enzyme carbonyl. A second tetrahedral intermediate forms, again stabilised by the oxyanion hole. This collapses, breaking the Ser-ester bond and releasing the carboxylate product. Ser195 is regenerated.

The triad works because each residue plays a specific role: Ser provides the nucleophile, His shuttles protons (acid-base catalysis), and Asp stabilises the positive charge on His through electrostatic interaction. The oxyanion hole provides transition-state stabilisation by hydrogen-bonding to the high-energy tetrahedral intermediate. Together, these strategies lower the activation energy by roughly 90 kJ/mol, giving a rate enhancement of approximately $10^{10}$ over the uncatalysed hydrolysis of a peptide bond in water.

What this tells us: the enzyme combines covalent catalysis (Ser ester intermediate), acid-base catalysis (His proton shuttle), and transition-state stabilisation (oxyanion hole) in a single active site to achieve catalytic power that no single strategy could deliver alone.

Check your understanding [Beginner]

Formal definition [Intermediate+]

Michaelis-Menten kinetics. The simplest enzyme mechanism:

$$\mathrm{E}+\mathrm{S}\underset{{\mathrm{k}}_{-1}}{\stackrel{{\mathrm{k}}_1}{\rightleftharpoons }}\mathrm{ES}\stackrel{{\mathrm{k}}_2}{\to }\mathrm{E}+\mathrm{P}$$

Under the steady-state approximation ($d[ES]/dt=0$), the rate equation is:

$$v=\frac{V_{max}[S]}{K_M+[S]}$$

where $V_{max}=k_2[E{]}_T$ (the total enzyme concentration times the turnover number) and $K_M=(k_{-1}+k_2)/k_1$ (the Michaelis constant). The turnover number $k_{cat}=V_{max}/[E{]}_T$ counts the substrate molecules converted to product per enzyme molecule per unit time when the enzyme is fully saturated.

Catalytic efficiency is $k_{cat}/K_M$, with units ${\mathrm{M}}^{-1}{\mathrm{s}}^{-1}$. The upper limit is the diffusion-controlled encounter rate, $\sim 10^8\text{–}10^9{\mathrm{M}}^{-1}{\mathrm{s}}^{-1}$. Enzymes approaching this limit are called "catalytically perfect" — every collision between enzyme and substrate produces product.

Catalytic strategies are classified by the type of chemical assistance the enzyme provides:

1. Acid-base catalysis. A side chain (His, Asp, Glu, Lys, Cys, Tyr) donates or accepts a proton. Example: His57 in chymotrypsin.

2. Covalent catalysis. A nucleophilic side chain (Ser, Cys, Lys, His) forms a transient covalent bond with the substrate. Example: Ser195 in chymotrypsin.

3. Metal ion catalysis. A bound metal ion (Zn, Mg, Fe, Mn, Cu) polarises bonds, stabilises charges, or generates nucleophiles. Example: Zn${}^{2+}$ in carbonic anhydrase.

4. Proximity and orientation effects. The enzyme binds multiple substrates and holds them in the correct orientation, increasing the effective local concentration and reducing the entropic cost of reaching the transition state.

5. Transition-state stabilisation. The active site is complementary to the transition state, not the substrate. The enzyme binds the transition state more tightly than the substrate, lowering the activation energy.

Counterexamples to common slips

• $K_M$ is not the binding constant. $K_M=(k_{-1}+k_2)/k_1$ equals the dissociation constant $K_d=k_{-1}/k_1$ only when $k_2\ll k_{-1}$ (rapid equilibrium). When $k_2$ is comparable to $k_{-1}$, $K_M$ exceeds $K_d$.

• Enzymes do not change the equilibrium. They accelerate both forward and reverse reactions equally. The ratio $k_{cat}^{fwd}/k_{cat}^{rev}=K_{eq}$ (the Haldane relationship).

• The catalytic triad is not the only mechanism for proteolysis. Cysteine proteases (papain) use Cys-His-Asn. Aspartyl proteases (HIV protease) use two Asp residues with an activated water. Metalloproteases (thermolysin) use a Zn-bound water as the nucleophile.

• Enzymes are not always proteins. Ribozymes — RNA enzymes — catalyse peptide bond formation in the ribosome, self-splicing of introns, and RNA cleavage. The ribosome's peptidyl transferase centre is entirely RNA, with no protein side chain within 18 angstroms of the catalytic site.

Key theorem with proof [Intermediate+]

Proposition (Derivation of the Michaelis-Menten equation from the steady-state approximation). For the mechanism $\mathrm{E}+\mathrm{S}\rightleftharpoons \mathrm{ES}\to \mathrm{E}+\mathrm{P}$, the rate $v=k_2[ES]$ is given by $v=V_{max}[S]/(K_M+[S])$ where $V_{max}=k_2[E{]}_T$ and $K_M=(k_{-1}+k_2)/k_1$.

Proof. The total enzyme concentration is $[E{]}_T=[E]+[ES]$. The steady-state approximation sets $d[ES]/dt=0$:

$$k_1[E][S]=k_{-1}[ES]+k_2[ES]=(k_{-1}+k_2)[ES]$$

Solve for $[ES]$:

$$[ES]=\frac{k_1[E][S]}{k_{-1}+k_2}$$

Substitute $[E]=[E{]}_T-[ES]$:

$$[ES]=\frac{k_1([E{]}_T-[ES])[S]}{k_{-1}+k_2}$$

$$[ES](k_{-1}+k_2)=k_1[E{]}_T[S]-k_1[ES][S]$$

$$[ES](k_{-1}+k_2+k_1[S])=k_1[E{]}_T[S]$$

$$[ES]=\frac{k_1[E{]}_T[S]}{k_{-1}+k_2+k_1[S]}=\frac{[E{]}_T[S]}{K_M+[S]}$$

where $K_M=(k_{-1}+k_2)/k_1$. The rate $v=k_2[ES]$:

$$v=\frac{k_2[E{]}_T[S]}{K_M+[S]}=\frac{V_{max}[S]}{K_M+[S]}$$

$■$

Bridge. The Michaelis-Menten framework builds toward the allosteric models in the Master tier, where the assumption of a single enzyme conformation is replaced by multiple interconverting states. The central insight that $K_M=(k_{-1}+k_2)/k_1$ appears again in the MWC allosteric model as the microscopic binding constant within each conformational state. This is exactly the rate-law formalism that underpins every quantitative treatment of enzyme catalysis, from the simplest single-substrate mechanism to the multi-subunit cooperative binding of hemoglobin. The foundational reason enzymes achieve their extraordinary rate enhancements is transition-state stabilisation, and the bridge is between the thermodynamic activation-barrier formalism of the Eyring equation and the kinetic parameters $k_{cat}$ and $K_M$ derived here.

Exercises [Intermediate+]

Covalent catalysis and the catalytic triad [Master]

The chymotrypsin mechanism is the paradigmatic example of covalent catalysis in biology, and its active-site architecture — the Ser-His-Asp catalytic triad — has evolved independently at least three times in different protease families. Understanding why the triad works, and what happens when individual components are removed, illuminates the principle that enzyme catalysis arises from the cooperative action of multiple strategies, not from any single residue acting alone.

Serine protease families and convergent evolution. The chymotrypsin/trypsin family (the "trypsin fold") and the subtilisin family (bacterial serine proteases) share the Ser-His-Asp triad but have no detectable sequence or structural homology — their protein scaffolds are entirely different. The triad in trypsin uses Ser195, His57, and Asp102 on a beta-barrel fold; the triad in subtilisin uses Ser221, His64, and Asp32 on an alpha/beta fold. The convergent appearance of the same three-residue arrangement in two unrelated scaffolds is strong evidence that the triad geometry is close to optimal for peptide-bond hydrolysis.

The three members of the trypsin family — chymotrypsin, trypsin, and elastase — share the same fold and catalytic triad but differ in their specificity pockets. Chymotrypsin has a large hydrophobic pocket that accommodates aromatic side chains (Phe, Tyr, Trp). Trypsin has an Asp189 at the bottom of the pocket, which forms an ionic bond with basic side chains (Lys, Arg), giving specificity for positively charged residues. Elastase has a shallow pocket blocked by Val216 and Thr226, restricting access to small aliphatic residues (Ala, Gly, Val). The catalytic chemistry is identical in all three; specificity is determined entirely by the shape and charge of the binding pocket adjacent to the active site.

Mechanism detail: acylation and deacylation. The acylation phase begins when the substrate peptide enters the oxyanion hole. His57, positioned by its hydrogen bond to Asp102, abstracts the proton from Ser195-OH. The charge-relay system (Asp stabilises the protonated form of His, which in turn promotes deprotonation of Ser) converts the modest nucleophile Ser-OH into the powerful nucleophile Ser-O${}^{-}$. This alkoxide attacks the substrate carbonyl carbon, forming the first tetrahedral intermediate with an oxyanion at the carbonyl oxygen. The oxyanion hole — backbone NH groups from Gly193 and Ser195 in chymotrypsin — donates two hydrogen bonds to the oxyanion, stabilising this high-energy species by an estimated 20–30 kJ/mol. The tetrahedral intermediate collapses as the C-N bond breaks; His57 donates its proton to the departing amine nitrogen (general acid catalysis), releasing the first product ($\mathrm{R}-\mathrm{N}{\mathrm{H}}_2$) and leaving the acyl group covalently attached to Ser195 as an ester.

The deacylation phase is the mirror image of acylation. A water molecule enters the active site and is deprotonated by His57 (now acting as a general base again), generating HO${}^{-}$. This hydroxide attacks the acyl-enzyme carbonyl, forming a second tetrahedral intermediate stabilised by the same oxyanion hole. Collapse of this intermediate breaks the Ser-ester bond and releases the carboxylate product. Ser195 is regenerated, and the enzyme is ready for another catalytic cycle.

The cooperative effect of triad mutations. Site-directed mutagenesis studies quantify the contribution of each triad residue. The Ala195 mutant (Ser195 removed) reduces $k_{cat}$ by a factor of approximately $10^6$. The Ala102 mutant (Asp102 removed) reduces $k_{cat}$ by approximately $10^3$. The Ala57 mutant (His57 removed) reduces $k_{cat}$ by approximately $10^3$. But the double mutant Ala195/Ala57 reduces $k_{cat}$ by more than $10^9$ — the effects are multiplicative, not additive. The triad residues cooperate: His enables Ser to act as a nucleophile by deprotonating it, and Asp enables His to do so by stabilising its charged form. Removing any one component collapses the catalytic network.

Cysteine proteases: the thiolate as nucleophile. The papain family uses a Cys-His-Asn (or Cys-His) catalytic dyad/triad. Cysteine's thiol (-SH) is more acidic than serine's hydroxyl ($p{K}_a\approx 8.3$ vs $\approx 13$), so at physiological pH the thiolate ($\mathrm{Cys}-{\mathrm{S}}^{-}$) is present at higher concentration than the serine alkoxide would be without the charge-relay system. The thiolate is also more polarisable and hence more nucleophilic toward soft electrophiles like the amide carbonyl. The papain mechanism parallels chymotrypsin: Cys25 thiolate attacks the carbonyl, forming a thioester acyl-enzyme intermediate, with His159 shuttling protons. The thioester intermediate is more reactive toward hydrolysis than the serine ester, which partly compensates for the absence of a dedicated oxyanion hole in some cysteine proteases (though papain does have one, formed by Gln19 and the backbone NH of Cys25).

Caspases, the proteases that execute programmed cell death (apoptosis), are also cysteine proteases. They cleave after aspartate residues with high specificity, using a Cys-His dyad. The specificity for Asp at the P1 position is enforced by an arginine residue in the S1 pocket that forms a salt bridge with the substrate's aspartate carboxylate. The catalytic chemistry — covalent thioester intermediate, oxyanion-hole stabilisation, general acid-base catalysis by His — is shared with papain.

Transition-state theory and enzyme design [Master]

The principle of transition-state stabilisation, first articulated by Pauling in 1948 ^{[Pauling 1948]}, has a direct and powerful pharmaceutical application: if the enzyme's active site is complementary to the transition state, then a stable molecule that mimics the transition-state geometry should bind more tightly than the substrate. Such molecules are transition-state analogues and are among the most potent enzyme inhibitors known, with dissociation constants in the picomolar to nanomolar range.

Wolfenden's quantitative framework. Wolfenden 1969 ^{[Wolfenden 1969]} estimated that transition-state analogues should bind enzymes $10^7$ to $10^{14}$ times more tightly than the substrates from which they are derived, based on the rate enhancements that enzymes achieve. This follows from the thermodynamic cycle: the enzyme binds the transition state with affinity proportional to the rate enhancement. An enzyme that accelerates a reaction by $10^{10}$ binds the transition state $10^{10}$-fold more tightly than the substrate. A stable molecule that mimics even part of the transition-state geometry and charge distribution should capture a substantial fraction of this binding energy.

Pharmaceutical transition-state analogues. Statins (atorvastatin, simvastatin) inhibit HMG-CoA reductase by mimicking the tetrahedral transition state of the HMG-CoA substrate. The statin's dihydroxyheptanoic acid moiety resembles the tetrahedral intermediate in the reduction of HMG-CoA to mevalonate. The two hydroxyl groups replace the oxyanion of the transition state, engaging the same hydrogen-bond donors in the active site. Statins bind with $K_i$ values in the nanomolar range, compared to the substrate's $K_M\approx 10\mu \mathrm{M}$ — a $10^4$-fold improvement in binding affinity arising from transition-state mimicry.

HIV protease inhibitors (saquinavir, ritonavir, darunavir) are transition-state analogues of the peptide substrate. They incorporate a non-hydrolysable hydroxylethylamine or hydroxyethylsulfonamide isostere in place of the scissile peptide bond. The hydroxyl group mimics the oxyanion of the tetrahedral intermediate, binding in the oxyanion hole but resisting hydrolysis because the C-N bond has been replaced by a C-CH(OH)-CH${}_2$-N linkage that cannot undergo the same fragmentation. Darunavir achieves picomolar binding affinity and remains effective against many protease-inhibitor-resistant HIV strains because it makes extensive hydrogen-bond contacts with the backbone atoms of the protease active site — contacts that are conserved even when the virus mutates its side chains.

Allopurinol and purine nucleoside phosphorylase. Allopurinol (used to treat gout) inhibits xanthine oxidase by mimicking the transition state of hypoxanthine oxidation. Xanthine oxidase catalyses the oxidation of hypoxanthine to xanthine and then xanthine to uric acid. Allopurinol is itself oxidised to oxypurinol (alloxanthine), which tightly resembles the planar transition state of the purine ring and binds the reduced molybdenum cofactor with high affinity, giving slow-onset tight-binding inhibition with $K_i\approx 10^{-10}$ M.

Catalytic antibodies (abzymes). If transition-state stabilisation is the key to enzymatic catalysis, then an antibody raised against a transition-state analogue should catalyse the corresponding reaction. Lerner and Schultz independently demonstrated this in 1986: antibodies raised against phosphonate esters (tetrahedral, negatively charged — mimicking the oxyanion transition state of ester hydrolysis) catalysed ester hydrolysis with rate enhancements of $10^3$ to $10^5$. The catalytic antibodies were less efficient than natural enzymes because the immune system does not optimise the active-site environment for general acid-base catalysis or covalent catalysis — the antibody provides binding energy but lacks the precisely positioned catalytic residues that natural enzymes evolve. Nevertheless, the experiment confirmed the transition-state hypothesis: binding energy alone, without sophisticated catalytic machinery, is sufficient for substantial rate enhancement.

Computational enzyme design. The Baker and Hilvert labs designed a retro-aldolase and a Kemp eliminase — enzymes for reactions that have no natural counterpart — by computationally matching transition-state stabilising residues to a protein scaffold. The initial designs had modest activity ($k_{cat}/K_M\approx 10$ to $10^3{\mathrm{M}}^{-1}{\mathrm{s}}^{-1}$), far below natural enzymes. Directed evolution (iterative rounds of random mutagenesis and selection) improved the activities by 4–6 orders of magnitude. The lesson: computational design can create a scaffold with correctly positioned catalytic residues, but the fine-tuning of dynamics, solvation, and second-shell interactions that natural selection achieves over millions of years still requires laboratory evolution to replicate. This connects enzyme mechanism to the broader field of protein engineering and to Frances Arnold's Nobel-Prize-winning work on directed evolution.

Cofactors and metal-ion catalysis [Master]

Many enzyme reactions involve chemistry that amino acid side chains alone cannot accomplish. The twenty proteinogenic amino acids provide nucleophiles (Ser, Cys, Lys), acids and bases (His, Asp, Glu), and hydrophobic contacts, but they cannot perform one-electron redox, transfer hydride, or activate inert substrates like molecular nitrogen. Enzymes solve this by recruiting cofactors — small organic molecules or metal ions that expand the catalytic repertoire of the active site.

Pyridoxal phosphate (PLP) and transamination. PLP, the active form of vitamin B6, is the cofactor for aminotransferases (transaminases), decarboxylases, and racemases. It forms a Schiff base (imine) with the amino group of the substrate, covalently anchoring it to the enzyme. The pyridine ring of PLP acts as an electron sink: when the C-H bond of the substrate amino acid is broken, the resulting carbanion is stabilised by delocalisation into the conjugated ring system. This lowers the $p{K}_a$ of the alpha C-H from approximately 40 (in a free amino acid) to approximately 20 (in the PLP-Schiff-base complex), making the proton removable by a modest active-site base.

In aspartate aminotransferase, PLP transfers the amino group from aspartate to alpha-ketoglutarate, producing oxaloacetate and glutamate. The mechanism proceeds through three stages: (1) aspartate forms a Schiff base with PLP (external aldimine), displacing the enzyme's Lys258 (internal aldimine); (2) the alpha-proton is abstracted, forming a quinonoid intermediate stabilised by delocalisation into the pyridine ring; (3) the intermediate is reprotonated at a different position, and hydrolysis releases oxaloacetate. The PLP is now bound as pyridoxamine phosphate (PMP); the reverse half-reaction transfers the amino group to alpha-ketoglutarate, regenerating PLP. The net reaction is a double displacement (ping-pong mechanism) with no free intermediate.

Thiamine pyrophosphate (TPP) and decarboxylation. TPP, the active form of vitamin B1, is the cofactor for pyruvate decarboxylase, pyruvate dehydrogenase, and transketolase. The thiazolium ring of TPP generates a carbanion (ylide) at C2 by deprotonation — the C2-H has a $p{K}_a$ of approximately 12–13 because the adjacent positively-charged nitrogen stabilises the carbanion. This ylide attacks the carbonyl carbon of pyruvate, forming a covalent adduct from which CO${}_2$ is eliminated. The resulting hydroxyethyl-TPP carbanion is again stabilised by the thiazolium ring, preventing it from undergoing unwanted side reactions. In pyruvate dehydrogenase, this carbanion is then transferred to lipoamide, producing acetyl-dihydrolipoamide and regenerating TPP.

NAD${}^{+}$/NADP${}^{+}$ and hydride transfer. Nicotinamide adenine dinucleotide (NAD${}^{+}$) and its phosphorylated form (NADP${}^{+}$) are the universal two-electron redox cofactors. The nicotinamide ring accepts a hydride ion (H${}^{-}$, a proton plus two electrons) at the C4 position, converting NAD${}^{+}$ to NADH. The reaction is stereospecific: each enzyme transfers the hydride to one specific face of the nicotinamide ring (A-face or B-face). Alcohol dehydrogenase, for example, transfers the pro-R hydrogen of ethanol to the A-face of NAD${}^{+}$, producing NADH and acetaldehyde. The thermodynamic driving force is substantial: the NAD${}^{+}$/NADH couple has $E_0^{\prime }=-0.32$ V, making NADH a strong biological reductant. NADPH, with the same redox chemistry but different regulation, is used primarily in biosynthetic (reductive) pathways.

Zinc in carbonic anhydrase. Carbonic anhydrase II is one of the fastest enzymes known ($k_{cat}\approx 10^6{\mathrm{s}}^{-1}$), catalysing the interconversion of CO${}_2$ and HCO${}_3^{-}$. The active site contains a Zn${}^{2+}$ ion coordinated by three His residues and one water molecule. The Zn${}^{2+}$ ion lowers the $p{K}_a$ of the bound water from 15.7 (bulk water) to approximately 7, so at physiological pH a substantial fraction exists as Zn-OH${}^{-}$. This zinc-hydroxide is the nucleophile that attacks CO${}_2$, forming Zn-HCO${}_3^{-}$. Bicarbonate is displaced by a new water molecule, and a proton is transferred from the zinc-bound water to the bulk solvent through a His64 shuttle residue. The rate-limiting step is proton transfer, not the chemical conversion of CO${}_2$.

Iron in cytochrome P450. Cytochrome P450 enzymes catalyse the insertion of one oxygen atom from O${}_2$ into unactivated C-H bonds — a reaction that is among the most challenging in chemistry. The active site contains an Fe${}^{2+}$ ion in a haem (iron-protoporphyrin IX) cofactor, coordinated by a cysteine thiolate as the axial ligand. The catalytic cycle proceeds through: (1) substrate binding, displacing the water ligand; (2) one-electron reduction of Fe${}^{3+}$ to Fe${}^{2+}$ by NADPH via cytochrome P450 reductase; (3) O${}_2$ binding to form Fe${}^{2+}$-O${}_2$; (4) a second one-electron reduction and protonation to form Fe${}^{3+}$-OOH (compound 0); (5) O-O bond heterolysis with protonation of the distal oxygen, releasing water and generating the reactive intermediate compound I (Fe${}^{4+}$=O with a porphyrin radical cation). Compound I abstracts a hydrogen atom from the substrate C-H, forming a substrate radical and Fe${}^{4+}$-OH. Radical recombination ("oxygen rebound") forms the hydroxylated product. The C-H hydroxylation is thermodynamically driven by the very high redox potential of compound I (estimated $E_0>1.5$ V).

Magnesium in kinases and polymerases. Mg${}^{2+}$ is the most abundant divalent cation in cells and serves as a cofactor in essentially every reaction involving phosphate transfer. Kinases bind Mg${}^{2+}$-ATP as the true substrate: the Mg${}^{2+}$ ion neutralises two of the three negative charges on ATP's triphosphate tail, reducing electrostatic repulsion between ATP and the substrate and correctly positioning the gamma-phosphate for nucleophilic attack by the substrate hydroxyl. DNA and RNA polymerases use two Mg${}^{2+}$ ions in their active sites — one activates the 3'-OH nucleophile of the growing strand, and the other stabilises the negative charge that develops on the leaving pyrophosphate. The two-metal-ion mechanism, first proposed by Steitz and Steitz 1993, is a general solution to the problem of phosphoryl transfer and is shared by DNA polymerases, RNA polymerases, reverse transcriptases, and many nucleases.

Iron-sulphur clusters. Ferredoxins and related proteins contain Fe/S clusters — [2Fe-2S], [3Fe-4S], or [4Fe-4S] — that mediate one-electron redox reactions. Each iron is coordinated by four sulphur atoms (from cysteine thiolates and inorganic sulphide) in a roughly tetrahedral geometry. The clusters delocalise the added electron over multiple iron and sulphur centres, lowering the reorganisation energy and enabling rapid electron transfer. In aconitase, a [4Fe-4S] cluster serves not as a redox centre but as a Lewis acid: one iron coordinates the substrate's hydroxyl group, facilitating the dehydration-hydration sequence that converts citrate to isocitrate in the TCA cycle.

Allosteric regulation and cooperative binding [Master]

Enzymes do not operate at constant rate in living cells. Their activity is regulated by feedback inhibition, cooperativity, and allosteric effectors — mechanisms that allow metabolic pathways to respond to the cell's needs. The quantitative framework for cooperative binding was established by the MWC (Monod-Wyman-Changeux) and KNF (Koshland-Nemethy-Filmer) models, both published in the mid-1960s. These models explain how the binding of a ligand at one site on a multi-subunit enzyme influences the binding affinity at distant sites — the phenomenon of allostery.

Hemoglobin: the paradigm of cooperativity. Hemoglobin (Hb) is a tetramer of two alpha and two beta subunits, each containing a haem group that binds one O${}_2$ molecule. Myoglobin (Mb), a monomeric oxygen-storage protein, has a hyperbolic O${}_2$ binding curve described by simple Michaelis-Menten (or Hill) behaviour: $Y=[O_2]/(K_d+[O_2])$. Hemoglobin's O${}_2$ binding curve is sigmoidal — the binding of the first O${}_2$ molecule facilitates the binding of subsequent ones. The degree of cooperativity is quantified by the Hill coefficient $n_H$. For Mb, $n_H=1.0$ (no cooperativity); for Hb, $n_H\approx 2.8$ (positive cooperativity, with a maximum possible value of 4 for a four-site system).

The structural basis for hemoglobin cooperativity was established by Max Perutz's X-ray structures of deoxy-Hb (T state, "tense") and oxy-Hb (R state, "relaxed"). In the T state, the haem iron is out of the porphyrin plane, and the proximal His is pulled toward the haem, constraining the F helix and stabilising salt bridges between subunits. When O${}_2$ binds, the iron moves into the porphyrin plane, pulling the proximal His and the F helix with it. This local motion breaks the inter-subunit salt bridges, shifting the entire tetramer toward the R state. The R state has higher O${}_2$ affinity because the constraint on the haem iron is released. The T-to-R transition is concerted — it affects all four subunits simultaneously, though the initial O${}_2$ binding event destabilises the T state and shifts the T/R equilibrium.

The MWC concerted model. Monod, Wyman, and Changeux 1965 ^{[MWC 1965]} proposed that the enzyme exists in two conformational states — T (low affinity) and R (high affinity) — in equilibrium described by the allosteric constant $L=[T_0]/[R_0]$. For Hb, $L\approx 10^5$ in the absence of ligand, meaning the T state is overwhelmingly favoured. Each ligand binds to the R state with microscopic dissociation constant $K_R$ and to the T state with $K_T=c\cdot K_R$, where $c<1$ (T state has lower affinity). The binding of each successive ligand shifts the T/R equilibrium toward R, because ligand-bound R is stabilised relative to ligand-bound T. The fractional saturation for a symmetric $n$-subunit system is:

$$Y=\frac{L\cdot c(1+c{)}^{n-1}[S{]}^n+(1+c[S]/K_R{)}^n}{L(1+c[S]/K_R{)}^n+(1+[S]/K_R{)}^n}$$

where $[S]$ is the ligand concentration. When $L\gg 1$ and $c\ll 1$ (strong T-state preference, much lower T-state affinity), the binding curve is sigmoidal. The MWC model predicts that heterotropic effectors (molecules binding at sites distinct from the active site) modulate cooperativity by shifting $L$: an activator stabilises R (decreasing $L$), an inhibitor stabilises T (increasing $L$). 2,3-Bisphosphoglycerate (2,3-BPG) is a physiological allosteric inhibitor of Hb that binds only to the T state in the central cavity, increasing $L$ and decreasing O${}_2$ affinity. This is why fetal Hb (which has lower 2,3-BPG affinity) has higher O${}_2$ affinity than adult Hb — it is less inhibited.

The KNF sequential model. Koshland, Nemethy, and Filmer 1966 proposed an alternative in which each subunit undergoes a local conformational change upon ligand binding (induced fit), and the change propagates to neighbouring subunits through altered subunit-subunit interfaces, changing their affinity. In the KNF model, there is no global T/R equilibrium; instead, the conformational change is sequential. The first ligand binding event induces a change in one subunit, which alters the interfaces with its neighbours, changing their affinity for ligand. The model can accommodate positive cooperativity (the induced change increases neighbour affinity), negative cooperativity (neighbour affinity decreases), or no cooperativity.

For hemoglobin, the MWC model provides a better fit to the O${}_2$ saturation data under most conditions, but the KNF model better describes some allosteric enzymes where the conformational change is genuinely sequential. In practice, many allosteric proteins show behaviour intermediate between the two models, and modern treatments use statistical-mechanical frameworks that generalise both.

Feedback inhibition and metabolic regulation. The most common form of allosteric regulation in metabolism is feedback inhibition: the final product of a pathway inhibits the first committed enzyme. In the biosynthesis of the amino acid isoleucine from threonine, threonine deaminase (the first enzyme in the pathway) is allosterically inhibited by isoleucine, the end product. This prevents the cell from wasting resources overproducing isoleucine. Phosphofructokinase-1 (PFK-1), a key regulatory enzyme in glycolysis, is allosterically activated by ADP and fructose-2,6-bisphosphate (signalling energy deficit) and inhibited by ATP and citrate (signalling energy sufficiency). PFK-1 is a tetrameric enzyme that displays sigmoidal fructose-6-phosphate kinetics with $n_H\approx 1.8$ in the absence of effectors; the activators increase the apparent affinity for fructose-6-phosphate (shifting the curve toward hyperbolic), while inhibitors decrease it (enhancing sigmoidicity). This layered regulation connects enzyme mechanism to the metabolic state of the cell 17.04.01.

Proposition (Catalytic efficiency bound). For the Michaelis-Menten mechanism $\mathrm{E}+\mathrm{S}\rightleftharpoons \mathrm{ES}\to \mathrm{E}+\mathrm{P}$, the catalytic efficiency $k_{cat}/K_M$ satisfies $k_{cat}/K_M\le k_1$, where $k_1$ is the rate constant for enzyme-substrate encounter.

Proof. By definition, $k_{cat}/K_M=k_2{k}_1/(k_{-1}+k_2)$. Since $k_2\ge 0$ and $k_{-1}\ge 0$, we have $k_2/(k_{-1}+k_2)\le 1$. Therefore $k_{cat}/K_M\le k_1$. Equality holds when $k_2\gg k_{-1}$, meaning every enzyme-substrate encounter proceeds to product. $\square$

Synthesis. The foundational reason enzyme catalysis achieves rate enhancements of $10^6$ to $10^{17}$ is the convergence of multiple catalytic strategies — covalent catalysis, transition-state stabilisation, metal-ion cofactors, and allosteric regulation — on a single active-site architecture optimised by evolution. The central insight unifying these strategies is that enzymes stabilise the transition state, not the substrate; this is exactly the principle Pauling identified in 1948 and Wolfenden quantified in 1969 with transition-state analog inhibitors, and it generalises from serine proteases to metalloenzymes to computationally designed catalysts. Putting these together with the MWC allosteric model, the pattern recurs: binding energy from non-catalytic interactions — distant allosteric sites, oxyanion-hole hydrogen bonds, metal-coordination geometry, PLP electron-sink delocalisation — is converted into catalytic power at the active site. The bridge is between the chemistry of individual catalytic residues and the physics of cooperative conformational change in multi-subunit enzymes, identifying the enzyme's binding energy with the activation-barrier reduction that defines catalytic proficiency.

Connections [Master]

• Acids and bases in organic chemistry 15.03.01. General acid-base catalysis by enzyme active-site residues (His, Asp, Glu, Cys) is a direct application of the proton-transfer chemistry developed in the organic acid-base unit. The $p{K}_a$ values of amino acid side chains determine which residue can act as a general acid or base at physiological pH, and the pKa perturbation by the protein environment is itself an exercise in organic acid-base reasoning.

• Carbonyl nucleophilic addition 15.07.01. Serine and cysteine proteases hydrolyse the peptide (amide) carbonyl bond by the same addition-elimination mechanism treated in carbonyl chemistry: nucleophilic attack on the carbonyl carbon, tetrahedral intermediate, collapse with leaving-group departure. The acyl-enzyme intermediate is an ester (serine proteases) or thioester (cysteine proteases), and the oxyanion-hole stabilisation of the tetrahedral intermediate is the enzymatic counterpart of the transition-state stabilisation invoked in non-enzymatic carbonyl chemistry.

• Chemical kinetics 14.08.01. Michaelis-Menten kinetics is a specialisation of the general rate-law framework: the steady-state approximation on the ES complex, the Arrhenius/Eyring activation-energy analysis, and the concepts of rate constant, order, and molecularity all transfer directly. The catalytic efficiency $k_{cat}/K_M$ and the diffusion limit are extensions of the kinetic machinery developed in the chemical kinetics unit.

• Cellular respiration — glycolysis and TCA cycle 17.04.01. Every enzyme-catalysed step in glycolysis and the TCA cycle uses one or more of the catalytic strategies developed here. Hexokinase uses metal-ion catalysis (Mg${}^{2+}$). Aldolase uses covalent catalysis (Schiff base with Lys). Citrate synthase uses acid-base catalysis (His and Asp). Aconitase uses an Fe/S cluster as a Lewis acid cofactor. The mechanistic detail for each enzyme traces back to the principles established in this unit.

• Amino acids and protein chemistry 15.12.01 pending. Enzymes are proteins whose catalytic power derives from the reactive side chains positioned in the active site by the tertiary fold. The serine protease catalytic triad (Ser-His-Asp), the cysteine protease mechanism (Cys-His), and metalloprotease zinc coordination (His, Glu, Asp) all exploit the nucleophilic and acid-base chemistry of amino acid side chains whose properties are detailed in the amino acid chemistry unit. Each catalytic strategy is a coherent deployment of individual amino acid reactivities.

• Nucleic acid chemistry 15.13.01 pending. DNA polymerases, RNA polymerases, ligases, and topoisomerases are enzyme-catalysed reactions operating on nucleic acid substrates. Phosphodiester bond formation by polymerases proceeds through a two-metal-ion mechanism, and the polymerase active site enforces Watson-Crick selectivity through geometric complementarity. Ribozymes demonstrate that the catalytic strategies formalised here are not limited to protein enzymes — RNA itself can deploy acid-base catalysis and metal-ion coordination.

• Translation 17.05.03 pending. Kinetic proofreading by EF-Tu at the ribosome shares its operating principle with enzyme catalytic discrimination: both use irreversible energy-consuming steps (GTP hydrolysis for EF-Tu, conformational changes for enzymes) to amplify small thermodynamic differences into large selectivity ratios. The Hopfield mechanism that underlies translational fidelity is the same principle that enzymes use for substrate specificity — specificity is bought with ATP or GTP hydrolysis.

Historical & philosophical context [Master]

Emil Fischer 1894 proposed the lock-and-key hypothesis ^{[Fischer 1894]}, arguing that the enzyme active site is a rigid template geometrically complementary to the substrate, like a lock accepting only one key. The model explained enzyme specificity but could not account for catalysis — why the enzyme speeds up the reaction, not merely binding the substrate. Linus Pauling 1948 provided the crucial complement ^{[Pauling 1948]}: enzymes are complementary not to the substrate but to the transition state of the reaction, and this complementarity lowers the activation energy. Daniel Koshland 1958 introduced the induced-fit model ^{[Koshland 1958]}, recognising that enzyme active sites are flexible — the substrate induces a conformational change that creates the complementary geometry, explaining both specificity (wrong substrates do not induce the correct fit) and catalysis (the induced fit preferentially stabilises the transition state).

Leonor Michaelis and Maud Menten 1913 ^{[Michaelis Menten 1913]} established the quantitative framework for enzyme kinetics, deriving the rate equation that bears their name from measurements of invertase-catalysed sucrose hydrolysis. Their work introduced the concept of the enzyme-substrate complex and the saturation behaviour that distinguishes enzyme catalysis from simple homogeneous catalysis. The steady-state reformulation by Briggs and Haldane 1925 extended the treatment to cases where the ES complex is not in rapid equilibrium.

Richard Wolfenden 1969 ^{[Wolfenden 1969]} demonstrated that stable transition-state analogues bind enzymes orders of magnitude more tightly than substrates, providing the first quantitative confirmation of Pauling's hypothesis and launching the field of transition-state-based drug design. Jacques Monod, Jeffries Wyman, and Jean-Pierre Changeux 1965 ^{[MWC 1965]} published the concerted allosteric model (MWC model), followed by Koshland, Nemethy, and Filmer 1966 with the sequential model (KNF model). Together, these two models established the quantitative framework for understanding cooperativity and allosteric regulation — phenomena that connect enzyme mechanism to the regulation of metabolism at the systems level.

Bibliography [Master]

@article{Fischer1894,
  author = {Fischer, Emil},
  title = {Einfluss der Configuration auf die Wirkung der Enzyme},
  journal = {Ber. Dtsch. Chem. Ges.},
  volume = {27},
  pages = {2985--2993},
  year = {1894},
}

@article{MichaelisMenten1913,
  author = {Michaelis, Leonor and Menten, Maud L.},
  title = {Die Kinetik der Invertinwirkung},
  journal = {Biochem. Z.},
  volume = {49},
  pages = {333--369},
  year = {1913},
}

@article{Pauling1948,
  author = {Pauling, Linus},
  title = {Chemical Achievement and Hope for the Future},
  journal = {Am. Sci.},
  volume = {36},
  pages = {51--58},
  year = {1948},
}

@article{Koshland1958,
  author = {Koshland, Daniel E.},
  title = {Application of a Theory of Enzyme Specificity to Protein Synthesis},
  journal = {Proc. Natl. Acad. Sci. USA},
  volume = {44},
  pages = {98--104},
  year = {1958},
}

@article{Wolfenden1969,
  author = {Wolfenden, Richard},
  title = {Transition state analogues for enzyme catalysis},
  journal = {Nature},
  volume = {223},
  pages = {704--705},
  year = {1969},
}

@article{MonodWymanChangeux1965,
  author = {Monod, Jacques and Wyman, Jeffries and Changeux, Jean-Pierre},
  title = {On the Nature of Allosteric Transitions: A Plausible Model},
  journal = {J. Mol. Biol.},
  volume = {12},
  pages = {88--118},
  year = {1965},
}

@article{KoshlandNemethyFilmer1966,
  author = {Koshland, Daniel E. and Nemethy, George and Filmer, David},
  title = {Comparison of Experimental Binding Data and Theoretical Models in Proteins Containing Subunits},
  journal = {Biochemistry},
  volume = {5},
  pages = {365--385},
  year = {1966},
}

@book{Fersht1999,
  author = {Fersht, Alan},
  title = {Enzyme Structure and Mechanism},
  edition = {2nd},
  publisher = {W. H. Freeman},
  year = {1999},
}

@book{Silverman2002,
  author = {Silverman, Richard B.},
  title = {The Organic Chemistry of Enzyme-Catalyzed Reactions},
  edition = {2nd},
  publisher = {Academic Press},
  year = {2002},
}

@book{VoetVoet2016,
  author = {Voet, Donald and Voet, Judith G.},
  title = {Biochemistry},
  edition = {5th},
  publisher = {Wiley},
  year = {2016},
}

@book{Lehninger2017,
  author = {Nelson, David L. and Cox, Michael M.},
  title = {Lehninger Principles of Biochemistry},
  edition = {7th},
  publisher = {W. H. Freeman},
  year = {2017},
}

@book{CareySundberg2007,
  author = {Carey, Francis A. and Sundberg, Richard J.},
  title = {Advanced Organic Chemistry, Part A: Structure and Mechanisms},
  edition = {5th},
  publisher = {Springer},
  year = {2007},
}